The expression of immunohistochemical markers estrogen receptor, progesterone receptor, Her-2-neu, p53 and Ki-67 in epithelial ovarian tumors and its correlation with clinicopathologic variables

Indian Journal of Pathology and Microbiology

Volumn 55, Issue 1, 2012, Pages 33-37

  Sylvia, Mary T ^a   Kumar, Surendra ^a   Dasari, Papa ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Epithelial ovarian tumors; Her 2 neu; Ki 67; p53; steroid receptors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; KI 67 ANTIGEN; PROGESTERONE RECEPTOR A; PROTEIN P53;

ADULT; ARTICLE; ASCITES; CANCER STAGING; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PATHOPHYSIOLOGY; POSTMENOPAUSE; PROTEIN EXPRESSION;

ADULT; CARCINOMA; FEMALE; HISTOCYTOCHEMISTRY; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSCOPY; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84860430125     PISSN: 03774929     EISSN: 09745130     Source Type: Journal    
DOI: 10.4103/0377-4929.94852     Document Type: Article

References (16)

1. Jernal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ, et al. Cancer statistics 2009. Cancer J Clin 2009;59:225-49.
2. Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, et al. Correlation of p53 mutations with resistance to platinum based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 2001;7:2984-97. (Pubitemid 32963815)
3. William E, Winter, Maxwell L, Tian C, Carison JW, Ozols RF, et al. Prognostic factors for stage 3 epithelial ovarian cancer: A gynecologic oncology group study. J Clin Oncol 2007;25:3621-7. (Pubitemid 47372600)
4. Damiao RD, Oshima CT, Stavale JN, Goncalves WJ. Analysis of the expression of estrogen receptor, progesterone receptor and chicken ovalbumin upstream promoter transcription factor I in ovarian epithelial cancers and normal ovaries. Oncol Rep 2007;18:25-32.
5. Agarwal N, Rao DL, Murgeshan K, Verma U, Mittal S, Buckshee K. Clinical evaluation of steroid receptors in ovarian neoplasms. Int J Gynecol Obstet 1987;25:145-9. (Pubitemid 17047952)
6. Buchynska LG, Iurchenko NP, Grinkevych VM, Nesina IP, Chekhun SV, Svintsitsky VS. Expression of the estrogen and progesterone receptors as prognostic factor in serous ovarian cancers. Exp Oncol 2009;31:48-51.
7. Hecht JL, Kotsopoulos J, Hankinson SE, Tworoger SS. Relationship between Epidemiologic Risk Factors and Hormone Receptor Expression in Ovarian Cancer: Results from the Nurses Health Study. Cancer Epidemiol Biomarkers Prev 2009;18:1624-30.
8. Lau KM, Mok SC, Ho SM. Expression of human estrogen receptor-A and-B, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci 1999;96:5722-7. (Pubitemid 29234685)
9. Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F. ERβ inhibits proliferation and invasion of breast cancer cells. Endocrinology 2001;142:4120-30. (Pubitemid 32802685)
10. Miller WR, Anderson TJ, Dixon JM. Antitumour effects of letrozole. Cancer Invest 2002;20:15-21.
11. Hellstrom I, Goodman G, Pullman J, Yang Y, Hellstrom KE. Overexpression of Her-2 in ovarian carcinomas. Cancer Res 2001;61:2420-3. (Pubitemid 32685817)
12. Levesque MA, Katsaros D, Yu H, Zola P, Sismondi P, Giardiana G, et al. Mutant p53 protein expression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995;75:1327-38.
13. Berchuck A, Kohler MF, Hopkins MP, Humphrey PA, Robboy SJ, Rodriguez GC, et al. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumours. Gynecol Oncol 1994;52:232-6. (Pubitemid 24064376)
14. Huettner PC, Weinberg DS, Large JM. Assesment of proliferative activity in ovarian neoplasms by flow and static cytometry. Correlation with prognostic features. Am J Pathol 1992;141:699-706.
15. Zorn KK, Tian C, McGuire WP, Hoskins WJ, Markman M, Muggia FM, et al. The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer 2009;1028-35.
16. Liu N, Wang X, Sheng X. The clinicopathological characteristics of triple negative epithelial ovarian cancer. J Clin Pathol 2010;63:240-3.